These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 29805706)

  • 1. Changes in the trends of initial treatment for newly diagnosed prostate cancer in Japan: a nationwide multi-institutional study.
    Kawai T; Onozawa M; Taguchi S; Shiota M; Sakamoto S; Yamamoto Y; Kitagawa Y; Nakagawa T; Hinotsu S; Kume H;
    Jpn J Clin Oncol; 2024 Sep; 54(9):1045-1051. PubMed ID: 38884136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors influencing prostate cancer patterns of care: An analysis of treatment variation using the SEER database.
    Burt LM; Shrieve DC; Tward JD
    Adv Radiat Oncol; 2018; 3(2):170-180. PubMed ID: 29904742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tissue-Based Genomic Testing in Prostate Cancer: 10-Year Analysis of National Trends on the Use of Prolaris, Decipher, ProMark, and Oncotype DX.
    Bologna E; Ditonno F; Licari LC; Franco A; Manfredi C; Mossack S; Pandolfo SD; De Nunzio C; Simone G; Leonardo C; Franco G
    Clin Pract; 2024 Mar; 14(2):508-520. PubMed ID: 38525718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MRI T2w Radiomics-Based Machine Learning Models in Imaging Simulated Biopsy Add Diagnostic Value to PI-RADS in Predicting Prostate Cancer: A Retrospective Diagnostic Study.
    Liu JC; Ruan XH; Chun TT; Yao C; Huang D; Wong HL; Lai CT; Tsang CF; Ho SH; Ng TL; Xu DF; Na R
    Cancers (Basel); 2024 Aug; 16(17):. PubMed ID: 39272801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single-site multiport vs. conventional multiport robot-assisted radical prostatectomy: A propensity score matching comparative study.
    Hou W; Wang B; Zhou L; Li L; Li C; Yuan P; Ouyang W; Yao H; Huang J; Yao K; Wang L
    Front Surg; 2022; 9():960605. PubMed ID: 36248365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PDZRN4 suppresses tumorigenesis and androgen therapy-resistance in prostate cancer.
    Jin P; Wu L; Zhang G; Yang B; Zhu B
    J Cancer; 2022; 13(7):2293-2300. PubMed ID: 35517421
    [No Abstract]   [Full Text] [Related]  

  • 7. Prostate Health Index (
    Yan JQ; Huang D; Huang JY; Ruan XH; Lin XL; Fang ZJ; Gao Y; Jiang HW; Wu YS; Na R; Xu DF
    Asian J Androl; 2022; 24(4):406-410. PubMed ID: 34782549
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of miR‑145 and testicular nuclear receptor 4 inhibition to reduce chemoresistance to docetaxel in prostate cancer.
    Zhu J; Qin P; Cao C; Dai G; Xu L; Yang D
    Oncol Rep; 2021 Mar; 45(3):963-974. PubMed ID: 33650661
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-Effectiveness Analysis of Prostate Health Index in Decision Making for Initial Prostate Biopsy.
    Huang D; Yang X; Wu Y; Lin X; Xu D; Na R; Xu J
    Front Oncol; 2020; 10():565382. PubMed ID: 33330035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radium-223 in Asian patients with castration-resistant prostate cancer with symptomatic bone metastases: A single-arm phase 3 study.
    Zhou T; Zhou F; Guo J; Shi H; Yao X; Guo H; Yuan J; Tian Y; Zhang X; Wang S; Jiang Y; Zou Q; Zhou D; Li H; Li F; Lee JL; Chen CH; Park SH; Ng QS; Ma J; Zheng R; Ding Q; Liu X; Li R; Krissel H; Wagner VJ; Sun Y
    Asia Pac J Clin Oncol; 2021 Dec; 17(6):462-470. PubMed ID: 33051982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of long-chain non-coding RNA GAS5 gene polymorphisms with prostate cancer risk and prognosis in Chinese Han population.
    Zhao L; Zheng W; Li C
    Medicine (Baltimore); 2020 Sep; 99(36):e21790. PubMed ID: 32899006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long non-coding RNA NORAD induces cell proliferation and migration in prostate cancer.
    Zhang H; Guo H
    J Int Med Res; 2019 Aug; 47(8):3898-3904. PubMed ID: 31342822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current Treatment for Low-Risk Prostate Cancer in China: A National Network Survey.
    Wei Y; Liu L; Li X; Song W; Zhong D; Cao X; Yuan D; Ming S; Zhang P; Wen Y;
    J Cancer; 2019; 10(6):1496-1502. PubMed ID: 31031859
    [No Abstract]   [Full Text] [Related]  

  • 14. Trends in Treatment for Prostate Cancer in China: Preliminary Patterns of Care Study in a Single Institution.
    Zhao F; Shen J; Yuan Z; Yu X; Jiang P; Zhong B; Xiang J; Ren G; Xie L; Yan S
    J Cancer; 2018; 9(10):1797-1803. PubMed ID: 29805706
    [No Abstract]   [Full Text] [Related]  

  • 15. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
    Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; Van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
    Eur Urol; 2011 Apr; 59(4):572-83. PubMed ID: 21315502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
    Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
    Actas Urol Esp; 2011; 35(10):565-79. PubMed ID: 21757258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Large institutional variations in use of androgen deprivation therapy with definitive radiotherapy in a population-based cohort of men with intermediate- and high-risk prostate cancer.
    Ong WL; Foroudi F; Evans S; Millar J
    BJU Int; 2017 Nov; 120 Suppl 3():35-42. PubMed ID: 28749017
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.